Abstract:Abstract Several cytokines involved in inflammatory pathologies signal via the Janus kinase-signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of JAKs and STATs determines the biological effects of each cytokine. JAK1 is involved in the signalling of ‘γc’ receptor cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21), pro-inflammatory cytokines including IL-6, as well as IFN. The critical position of JAK1 downstream of these cytokines suggests that JAK1-selective inhibitors are comparable to non-selective ones, without the unwanted consequences of JAK2- or JAK3-blockade. JAK inhibition has led to a better understanding of the biology of synovial inflammation and bone homeostasis. Moreover, the efficacy of non-selective JAK inhibitors and novel JAK1-selective drugs in RA supports a role for JAK1 in its pathogenesis. JAK1-selective drugs are also showing promise in axial spondyloarthritis, suggesting that they may target additional regulatory pathways that impact cytokines such as TNF and IL-17A, which do not use JAKs. Additionally, evidence now supports a JAK1 predominance in the signalling of IL-6 and oncostatin M, and indirectly, of TNF in synovial fibroblasts, macrophages and endothelial cells. Notably, bone homeostasis is also dependent on cytokines relying on JAK1 signalling to promote receptor activator of NF-κB ligand expression in osteoblasts and T cells, contributing to osteoclastogenesis. Here, the contribution of JAK1 over other kinases is unclear. While beneficial effects of JAK inhibitors on bone erosion are supported by preclinical and clinical data, effects on new bone formation in axial spondyloarthritis requires additional study. CME: This supplement is CME Accredited. To receive a CME certificate of participation, you should: Read all the papers in the supplement Register or log in at www.paradigmmc.com/962 to complete and submit the post activity assessment. You must answer 70% of the questions correctly to earn credit. You will have unlimited opportunities to successfully complete the assessment. You will receive a maximum of 7.0 AMA PRA Category 1 CreditsTM upon successful completion of the assessment.

JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

JAK/STAT pathway and molecular mechanism in bone remodeling

Wnt Signaling:Essential Roles in Osteoblast Differentiation,bone Metabolism and Therapeutic Implications for Bone and Skeletal Disorders

The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathology

The JAK/STAT Pathway in Skeletal Muscle Pathophysiology

The JAK-STAT pathway: from structural biology to cytokine engineering

The JAK/STAT signaling pathway: from bench to clinic

JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

JAK/STAT signaling pathway in the process of differentiation and maturation of Dendritic calls

Signaling by STATs.

JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Dynamics and non-canonical aspects of JAK/STAT signalling

The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms

The potential roles of JAK/STAT signaling in the progression of osteoarthritis

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

Inhibition of STAT1 accelerates bone fracture healing

JAK1: Number one in the family; number one in inflammation?

JAK-STAT signaling maintains homeostasis in T cells and macrophages